Vemurafenib Retreatment Deemed Effective in R/R Hairy Cell Leukemia
Frequent relapses after vemurafenib monotherapy in the R/R HCL setting may be from persistent residual disease after a limited duration of treatment...
Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19
Because patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a subtype of NHL, have both a higher risk of poor outcomes from COVID-19 and immune system defects as a result of their therapy and cancer itself...
Nilotinib Demonstrates Greater Efficacy Than Imatinib in CML
Treatment with nilotinib was more effective in inducing deep molecular response (MR 4.5) than imatinib for patients with chronic myeloid leukemia...
Updated Results from the Phase I/II Study of Pirtobrutinib for Previously Treated CLL/SLL
Pirtobrutinib was shown to have efficacy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a Bruton tyrosine kinase inhibitor...
Fixed-Duration Venetoclax Consolidation Does Not Improve Responses After Venetoclax Plus Obinutuzumab in CLL
A 12-cycle venetoclax consolidation regimen following fixed-duration venetoclax plus obinutuzumab increased the duration of side effects and did not prevent the loss of measurable residual disease (MRD)-negative response and disease relapse risk in patients with previously untreated chronic lymphocytic leukemia...
Ibrutinib, Venetoclax, and Obinutuzumab Triplet Shows Promise for Untreated, High-Risk CLL
A triple combination of ibrutinib, venetoclax, and obinutuzumab led to high rates of complete response (CR) and estimated 24-month survival in patients with untreated high-risk chronic lymphocytic leukemia...
